Endoluminal therapy for esophageal disease: an introduction.
This introductory article summarizes decades of research from many dedicated gastrointestinal endoscopists. It provides a background to Barrett esophagus (BE), exploring the risk of progression to dysplasia and esophageal adenocarcinoma. Two premalignant conditions, BE and colon adenoma, are compared, including their progression to esophageal adenocarcinoma and colon and rectal carcinoma, respectively. A comparison of the risks of surgical treatment and post-surgical complications of these cancers and of the strikingly different paradigms for their prevention is presented. The article concludes with the rationale for endoscopic treatment of Barrett disease.
Wolfsen
Herbert C
HC
Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL 32224, USA. wolfsen.herbert@mayo.edu
D000230:Adenocarcinoma / Q000209:etiology / Q000517:prevention & control; D000236:Adenoma / Q000473:pathology; D001471:Barrett Esophagus / Q000150:complications / Q000473:pathology / Q000601:surgery*; D002277:Carcinoma / Q000209:etiology / Q000517:prevention & control; D003110:Colonic Neoplasms / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000209:etiology / Q000517:prevention & control; D004947:Esophagus / Q000473:pathology / Q000601:surgery*; D006801:Humans; D011230:Precancerous Conditions / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D012004:Rectal Neoplasms / Q000209:etiology / Q000517:prevention & control; D018570:Risk Assessment